The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition.
Hemostemix believes its new cell therapy platform can help treat peripheral artery disease, congestive heart failure, cardiomyopathy and other serious medical conditions. The company plans on scooping up multiple practices to conduct additional research and increase the use of its platform.
There is a risk of certain pericardial patches not being as strong or durable as needed. Customers are urged to identify, quarantine and replace these devices.
Between 20% to 24% of all breast cancers diagnosed during a decade-long period were found in women between the ages of 18 to 49, according to research presented at RSNA 2025.
Eric Cordes, MD, 63, of Simi Valley, California, was a highly respected diagnostic specialist with Adventist Health Simi Valley and Focus Medical Imaging.
PPM is still relatively common after TAVR, especially among patients with a small aortic annulus. What can be done to minimize the risk of PPM? Does valve type play a role? Researchers explored those questions, and many others.
The figure includes about $208.5 million for initial board certification and another $775.3 million for maintaining the designation over a 35-year career.
Hospitals and physicians are pressing lawmakers to pass two previously proposed pieces of legislation that allow international medical graduates to work here longer.
The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition.
Hemostemix believes its new cell therapy platform can help treat peripheral artery disease, congestive heart failure, cardiomyopathy and other serious medical conditions. The company plans on scooping up multiple practices to conduct additional research and increase the use of its platform.
